Cargando…

Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita

Epidermolysis bullosa acquisita (EBA) is a subepidermal autoimmune bullous disease caused by autoantibodies targeting type VII collagen (COL7). It is characterized by inflammation and subepidermal blistering mainly through immune complex (IC)-mediated activation of neutrophils. In experimental EBA,...

Descripción completa

Detalles Bibliográficos
Autores principales: Haeger, Swantje C., Kridin, Khalaf, Pieper, Mario, Griewahn, Laura, Nimmerjahn, Falk, Zillikens, Detlef, König, Peter, Ludwig, Ralf J., Hundt, Jennifer E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606225/
https://www.ncbi.nlm.nih.gov/pubmed/36311755
http://dx.doi.org/10.3389/fimmu.2022.938306
_version_ 1784818245759401984
author Haeger, Swantje C.
Kridin, Khalaf
Pieper, Mario
Griewahn, Laura
Nimmerjahn, Falk
Zillikens, Detlef
König, Peter
Ludwig, Ralf J.
Hundt, Jennifer E.
author_facet Haeger, Swantje C.
Kridin, Khalaf
Pieper, Mario
Griewahn, Laura
Nimmerjahn, Falk
Zillikens, Detlef
König, Peter
Ludwig, Ralf J.
Hundt, Jennifer E.
author_sort Haeger, Swantje C.
collection PubMed
description Epidermolysis bullosa acquisita (EBA) is a subepidermal autoimmune bullous disease caused by autoantibodies targeting type VII collagen (COL7). It is characterized by inflammation and subepidermal blistering mainly through immune complex (IC)-mediated activation of neutrophils. In experimental EBA, binding of neutrophils to ICs in the skin and induction of clinical disease depends on the expression of the Fc gamma receptor (FcγR) IV. As activating FcγR mediate both neutrophil extravasation and activation, we used multiphoton imaging to obtain further insights into the mechanistic contribution of FcγRIV in the pathogenesis of EBA. First, we demonstrated that blocking FcγRIV function completely protects LysM-eGFP mice against induction of antibody transfer-induced EBA. To visualize the interactions of anti-COL7 IgG and neutrophils in vivo, fluorescently labeled anti-COL7 IgG was injected into LysM-eGFP mice. Multiphoton microscopy was sequentially performed over a period of 8 days. At all time points, we observed a significantly higher extravasation of neutrophils into the skin of mice treated with anti-FcγRIV antibody compared to controls. However, the percentage of detected neutrophils localized to the target antigen along the dermal-epidermal junction was comparable between both groups. Additionally, reactive oxygen release and migration in vitro assay data demonstrate that FcγRIV antibody treatment inhibits the activation, but not the migration, of neutrophils. Our findings underscore the importance of advanced in vivo imaging techniques to understand the complexity of IC-mediated neutrophil-dependent inflammation, and indicate that the therapeutic utility of FcγRIV blockade is achieved through impairment of IC-mediated neutrophil activation.
format Online
Article
Text
id pubmed-9606225
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96062252022-10-28 Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita Haeger, Swantje C. Kridin, Khalaf Pieper, Mario Griewahn, Laura Nimmerjahn, Falk Zillikens, Detlef König, Peter Ludwig, Ralf J. Hundt, Jennifer E. Front Immunol Immunology Epidermolysis bullosa acquisita (EBA) is a subepidermal autoimmune bullous disease caused by autoantibodies targeting type VII collagen (COL7). It is characterized by inflammation and subepidermal blistering mainly through immune complex (IC)-mediated activation of neutrophils. In experimental EBA, binding of neutrophils to ICs in the skin and induction of clinical disease depends on the expression of the Fc gamma receptor (FcγR) IV. As activating FcγR mediate both neutrophil extravasation and activation, we used multiphoton imaging to obtain further insights into the mechanistic contribution of FcγRIV in the pathogenesis of EBA. First, we demonstrated that blocking FcγRIV function completely protects LysM-eGFP mice against induction of antibody transfer-induced EBA. To visualize the interactions of anti-COL7 IgG and neutrophils in vivo, fluorescently labeled anti-COL7 IgG was injected into LysM-eGFP mice. Multiphoton microscopy was sequentially performed over a period of 8 days. At all time points, we observed a significantly higher extravasation of neutrophils into the skin of mice treated with anti-FcγRIV antibody compared to controls. However, the percentage of detected neutrophils localized to the target antigen along the dermal-epidermal junction was comparable between both groups. Additionally, reactive oxygen release and migration in vitro assay data demonstrate that FcγRIV antibody treatment inhibits the activation, but not the migration, of neutrophils. Our findings underscore the importance of advanced in vivo imaging techniques to understand the complexity of IC-mediated neutrophil-dependent inflammation, and indicate that the therapeutic utility of FcγRIV blockade is achieved through impairment of IC-mediated neutrophil activation. Frontiers Media S.A. 2022-10-13 /pmc/articles/PMC9606225/ /pubmed/36311755 http://dx.doi.org/10.3389/fimmu.2022.938306 Text en Copyright © 2022 Haeger, Kridin, Pieper, Griewahn, Nimmerjahn, Zillikens, König, Ludwig and Hundt https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Haeger, Swantje C.
Kridin, Khalaf
Pieper, Mario
Griewahn, Laura
Nimmerjahn, Falk
Zillikens, Detlef
König, Peter
Ludwig, Ralf J.
Hundt, Jennifer E.
Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita
title Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita
title_full Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita
title_fullStr Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita
title_full_unstemmed Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita
title_short Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita
title_sort therapeutic effects of fc gamma riv inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606225/
https://www.ncbi.nlm.nih.gov/pubmed/36311755
http://dx.doi.org/10.3389/fimmu.2022.938306
work_keys_str_mv AT haegerswantjec therapeuticeffectsoffcgammarivinhibitionaremediatedbyselectivelyblockingimmunecomplexinducedneutrophilactivationinepidermolysisbullosaacquisita
AT kridinkhalaf therapeuticeffectsoffcgammarivinhibitionaremediatedbyselectivelyblockingimmunecomplexinducedneutrophilactivationinepidermolysisbullosaacquisita
AT piepermario therapeuticeffectsoffcgammarivinhibitionaremediatedbyselectivelyblockingimmunecomplexinducedneutrophilactivationinepidermolysisbullosaacquisita
AT griewahnlaura therapeuticeffectsoffcgammarivinhibitionaremediatedbyselectivelyblockingimmunecomplexinducedneutrophilactivationinepidermolysisbullosaacquisita
AT nimmerjahnfalk therapeuticeffectsoffcgammarivinhibitionaremediatedbyselectivelyblockingimmunecomplexinducedneutrophilactivationinepidermolysisbullosaacquisita
AT zillikensdetlef therapeuticeffectsoffcgammarivinhibitionaremediatedbyselectivelyblockingimmunecomplexinducedneutrophilactivationinepidermolysisbullosaacquisita
AT konigpeter therapeuticeffectsoffcgammarivinhibitionaremediatedbyselectivelyblockingimmunecomplexinducedneutrophilactivationinepidermolysisbullosaacquisita
AT ludwigralfj therapeuticeffectsoffcgammarivinhibitionaremediatedbyselectivelyblockingimmunecomplexinducedneutrophilactivationinepidermolysisbullosaacquisita
AT hundtjennifere therapeuticeffectsoffcgammarivinhibitionaremediatedbyselectivelyblockingimmunecomplexinducedneutrophilactivationinepidermolysisbullosaacquisita